Equity Profile

JNJ

Johnson & Johnson

Health CarePharmaceuticals$620.5B

Jul15Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Johnson & Johnson (JNJ) is a leading health care company that develops and manufactures pharmaceuticals, medical devices, and consumer health products. With a market cap of $621 billion, it plays a significant role in the health care sector, focusing on innovation and addressing global health challenges.

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of common stock.

$2.84

Revenue

Total revenue provides insight into the company's sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, exceeding expectations by 1.09%. The stock rose by 0.90% the following day, indicating a positive market reaction.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Johnson & Johnson to report solid earnings, with a consensus EPS of $2.84 and revenue of $25.0 billion. The company has a strong track record of beating earnings estimates, which could lead to a positive market reaction.

Bull Case

If JNJ beats the EPS estimate and demonstrates strong revenue growth, it could reinforce investor confidence and drive the stock higher, especially given its historical performance of exceeding estimates.

Bear Case

Conversely, if JNJ fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied move priced into the options market.

Key Metrics to Watch

EPS

$2.84

Earnings per share (EPS) is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of common stock.

Revenue

$25.0B

Total revenue provides insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will JNJ's EPS exceed the consensus estimate of $2.84?

A beat on EPS could reinforce the company's strong earnings momentum and positively influence investor sentiment.

What guidance will management provide regarding future revenue growth?

Clear guidance on revenue growth will be crucial for assessing the company's outlook and could impact stock performance significantly.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate JNJ's ability to capitalize on new product launches and market expansion, which could drive higher-than-expected revenue growth.

Supporting Evidence

JNJ has consistently beaten EPS estimates over the past quarters, indicating strong underlying performance.

The options market is pricing a larger move than historical averages, suggesting that investors anticipate significant news.

Recent product innovations may not be fully reflected in analyst estimates, providing upside potential.

Key Risk

If revenue growth comes in below $24.6 billion, it could challenge the bullish consensus on the company's performance.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether JNJ can maintain its strong earnings trajectory amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility based on the results.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests the stock could rise by around 1.22% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further commentary from management.

Miss

A miss on earnings could lead to a decline, with historical patterns indicating a potential drop of around 1.22% or more.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue growth and potential challenges.
5Responses to questions about regulatory impacts on product lines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of common stock.

$2.84

Revenue

Total revenue provides insight into the company's sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, exceeding expectations by 1.09%. The stock rose by 0.90% the following day, indicating a positive market reaction.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

Bear Case

Conversely, if JNJ fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied move priced into the options market.

Key Metrics to Watch

EPS

$2.84

Earnings per share (EPS) is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of common stock.

Revenue

$25.0B

Total revenue provides insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will JNJ's EPS exceed the consensus estimate of $2.84?

A beat on EPS could reinforce the company's strong earnings momentum and positively influence investor sentiment.

What guidance will management provide regarding future revenue growth?

Clear guidance on revenue growth will be crucial for assessing the company's outlook and could impact stock performance significantly.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate JNJ's ability to capitalize on new product launches and market expansion, which could drive higher-than-expected revenue growth.

Supporting Evidence

JNJ has consistently beaten EPS estimates over the past quarters, indicating strong underlying performance.

The options market is pricing a larger move than historical averages, suggesting that investors anticipate significant news.

Recent product innovations may not be fully reflected in analyst estimates, providing upside potential.

Key Risk

If revenue growth comes in below $24.6 billion, it could challenge the bullish consensus on the company's performance.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether JNJ can maintain its strong earnings trajectory amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility based on the results.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests the stock could rise by around 1.22% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further commentary from management.

Miss

A miss on earnings could lead to a decline, with historical patterns indicating a potential drop of around 1.22% or more.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue growth and potential challenges.
5Responses to questions about regulatory impacts on product lines.